Key result
Poor cardiovascular health linked to ~10-fold greater risk of advanced liver fibrosis versus ideal health.
Why the study?
The association between cardiovascular health metrics and the severity of hepatic steatosis and liver fibrosis detected by transient elastography was unknown.
Is adherence to ideal cardiovascular health metrics associated with reduced severity of hepatic steatosis and liver fibrosis?
Cross-Sectional (n=2,679)
Is adherence to ideal cardiovascular health metrics associated with reduced severity of hepatic steatosis and liver fibrosis?
Effect estimate: CAP decreased by 8.565 units and LSM decreased by 0.274 units per 1-unit increase in CVH metric
Adherence to ideal cardiovascular health metrics (Life's Simple 7) is associated with a significantly lower risk and severity of hepatic steatosis and liver fibrosis.
Life's Simple 7 (LS7) is the American Heart Association's (AHA) proposal for a healthy lifestyle, also known as cardiovascular health (CVH) metrics. However, the association between CVH metrics and the severity of hepatic steatosis and liver fibrosis detected by transient elastography is unknown. We performed a cross-sectional study using the data from the 2017-2018 National Health and Nutrition Examination Survey (NHANES) cycle. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were used to evaluate the severity of hepatic steatosis and liver fibrosis and to define NAFLD, advanced liver fibrosis, and cirrhosis. A total of 2679 participants were included. Multivariate linear regression analysis revealed that per 1-unit increase in the CVH metric, CAP and LSM decreased by 8.565 units and 0.274 units, respectively. In the multivariate logistic regression analysis, the risk of NAFLD, advanced liver fibrosis, and cirrhosis were 7, 10, and 6 times higher in the poor CVH group than in the ideal CVH group. Subgroup analysis indicated that CVD patients and non-Hispanic whites could benefit more from ideal CVH. In conclusion, adherence to ideal CVH metrics, as proposed by the AHA, can significantly reduce the risk of hepatic steatosis and liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) conducted a cross-sectional in Hepatic steatosis and liver fibrosis (n=2,679). Cardiovascular health (CVH) metrics (Life's Simple 7) vs. Poor CVH group was evaluated on Severity of hepatic steatosis (CAP) and liver fibrosis (LSM) (CAP decreased by 8.565 units and LSM decreased by 0.274 units per 1-unit increase in CVH metric). Poor cardiovascular health was associated with a 7, 10, and 6 times higher risk of NAFLD, advanced liver fibrosis, and cirrhosis compared to ideal cardiovascular health.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: